EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

CCNP Innovations in Neuropsychopharmacology Award

Gabriella Gobbi

Journal of Psychiatry and Neuroscience · 2024

DOI: 10.1503/jpn.240037 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Psychiatry and Neuroscience, 2024. Verfasst von Gabriella Gobbi. Beteiligte Einrichtung: From the Department of Psychiatry and the McGill University Health Centre, McGill University, Montréal, Que. gabriella.gobbi@mcgill.ca. Hauptthemen laut MEDLINE: Hallucinogens, Spirituality, Brain, Psychopharmacology. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 179 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For 3000 years, psychedelics have been used in religious contexts to enhance spiritual thinking, well-being, and a sense of community. In the last few years, a renaissance in the use of psychedelic drugs for mental disorders has occurred in Western society; consequently, a pressing scientific need to elucidate the intricate mechanisms underlying their actions has arisen. Psychedelics mainly bind to serotonin (5-HT) receptors, particularly 5-HT 2A receptors, but may also bind to other receptors. Unlike conventional psychotropic drugs used in psychiatry, psychedelics introduce a distinctive complexity. They not only engage in receptor activation, but also exert influence over specific neural circuits, thereby facilitating transformative cognitive experiences and fostering what many have identified as a spiritual contemplation or mystical experience. This comprehensive review describes clinical studies that have examined the propensity of psychedelics to enhance spiritual, mystical, and transcendent cognitive states. This multifaceted nature, encompassing diverse components and paradigms, necessitates careful consideration during the investigation of psychedelic mechanisms of action to avoid oversimplification. The present review endeavours to elucidate the mechanisms underlying the actions of 2 principal psychedelic substances, psilocybin and lysergic acid diethylamide (LSD), with a focus on monoamine and glutamate receptor mechanisms; molecular aspects, such as neuroplasticity and epigenetics; as well as the impact of psychedelics on brain circuits, including the default mode network and the cortico–striato–thalamo–cortical network. Given their distinctive and intricate mechanisms of action, psychedelics necessitate a novel conceptual framework in psychiatry, offering insight into the treatment of mental health disorders and facilitating the integration of the realms of brain, mind, and spirituality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HallucinogensSpiritualityBrainPsychopharmacologyAwards and PrizesHumansMental Disorders

Substanzen

Hallucinogens

Autor:innen und Institutionen

  • From the Department of Psychiatry and the McGill University Health Centre, McGill University, Montréal, Que. gabriella.gobbi@mcgill.ca.

Förderung

  • CIHR

Zitieren

APA

Gobbi, G. (2024). CCNP Innovations in Neuropsychopharmacology Award. Journal of Psychiatry and Neuroscience. https://doi.org/10.1503/jpn.240037

Vancouver

Gobbi G. CCNP Innovations in Neuropsychopharmacology Award. Journal of Psychiatry and Neuroscience. 2024. doi:10.1503/jpn.240037

BibTeX
@article{Gobbi2024,
  author = {Gobbi, Gabriella},
  title = {CCNP Innovations in Neuropsychopharmacology Award},
  journal = {Journal of Psychiatry and Neuroscience},
  year = {2024},
  doi = {10.1503/jpn.240037}
}
Kostenlos starten →